novo nordisk glp-1 receptor agonist Cardiovascular Protective Properties of Agonists: More than Just Diabetic and Weight Loss Drugs Novo Nordisk expands patient access

Doctors report patients transitioning from nightly CPAP dependence to minimal usage or none at all after significant weight loss 34

Despite these encouraging observations, PWS remains a rare condition with limited large-scale trial data specifically examining GLP-1 efficacy

Insulin Treatment Source: Polaris Market Research Analysis What is Driving the GLP-1 Receptor Agonist Market

In contrast, a multicenter retrospective cohort study, including a higher-risk population (23% with CKD) reported slower eGFR decline and lower risks of CKD progression and doubling of serum creatinine among SGLT2 inhibitor users compared with GLP-1 receptor agonist users

Carrying extra weight doesnt just affect appearance